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The monoclonality of the T cell receptor g-chain
gene was analyzed by polymerase chain reaction in
skin and blood specimens of 85 patients with
cutaneous T cell lymphomas including 67 mycosis
fungoides, seven SeÂzary syndromes, and 11 CD30±
nonepidermotropic cutaneous T cell lymphomas. A
cutaneous T cell clone was detected in 69% of myco-
sis fungoides and 100% of SeÂzary syndromes. This
frequency varied according to the clinical stage: 57%
in early stages (Ia±IIa) to 96% in advanced stages
(IIb±IV, SeÂzary syndrome). A peripheral blood T cell
clone was detected in 42% of early stages and in 74%
of late stages but was identical to the cutaneous one
in 15% and in 63%, respectively. A signi®cant associ-
ation between initial clinical stage and T cell mono-
clonality was observed. In nonepidermotropic
cutaneous T cell lymphomas, T cell monoclonality
was detected in 55% of skin and 36% of blood
samples. Univariate and multivariate analyses showed
that, besides the initial clinical stage, an identical
cutaneous and blood T cell clone was an independ-
ent prognostic factor for disease progression of
mycosis fungoides/SeÂzary syndrome (hazard ratio
3.4, 95% con®dence interval 1.4±9.9). Parallel poly-
merase chain reaction study of skin and blood speci-
mens may therefore provide an initial prognostic
marker that could help to monitor therapeutic strat-
egies. A fully prospective study, with simultaneous
therapeutic trials, needs to be done to con®rm our
®ndings and to include treatment variables in the
statistical analysis. Key words: clonality/mycosis fun-
goides/cutaneous lymphomas. J Invest Dermatol 117:920±
926, 2001
M
ycosis fungoides (MF) is the most frequent
cutaneous T cell lymphoma (CTCL) and is
characterized by a prolonged indolent evolution
over several years or decades [5 y survival, 87%
(Willemze et al, 1997)] and an epidermotropic
in®ltrate of cerebriform cells. SeÂzary syndrome (SS) consists in its
leukemic counterpart with circulating cerebriform T cell lympho-
cytes (SeÂzary cells) associated with in®ltrated erythroderma and
generalized lymphadenopathy. Unlike MF, SS has a rapidly poor
prognosis [5 y survival, 11% (Willemze et al, 1997)]. Adverse
prognostic factors of MF/SS consist in age over 60 y (Diamandidou
et al, 1999), skin involvement (T staging) (Marti et al, 1991;
Zackheim et al, 1999), extracutaneous spread (Marti et al, 1991),
presence of SeÂzary/atypical cells in the peripheral blood (Kim et al,
1995), and high lactate dehydrogenase levels (Marti et al, 1991;
Diamandidou et al, 1999). Except for age, most of these factors are
not predictive of MF/SS aggressiveness at initial diagnosis, but are
correlated with the advanced stage of the disease. The group of
nonepidermotropic CTCL is heterogeneous and subdivided into
several entities according to the size of the lymphomatous cells and
to the expression of CD30 antigen (Willemze et al, 1997).
Although the group of CD30± nonepidermotropic CTCL is still
incompletely de®ned (Willemze et al, 1997), the CD30+ none-
pidermotropic CTCL is a separate entity of good prognosis with a
95% 5 y survival and different biologic behavior such as
spontaneous regression (Paulli et al, 1995; Willemze et al, 1997;
Vergier et al, 1998).
The diagnosis of CTCL relies on clinicopathologic characteris-
tics but may be dif®cult especially at early stages. The detection of a
dominant T cell clone in skin biopsy has been found as an
additional argument for the diagnosis of CTCL (Weiss et al, 1985;
Zelickson et al, 1991). Indeed, polymerase chain reaction (PCR)
allowed the detection of monoclonal rearrangement of the T cell
receptor g chain (TCR-g) gene in 53%±90% of MF/SS (Wood
et al, 1994; Theodorou et al, 1995; Muche et al, 1997; Delfau-
Larue et al, 1998a). The detection of cutaneous T cell mono-
clonality is more frequently achieved in advanced stages with
in®ltrated or tumoral lesions (73%±100%) than in MF with patch/
plaque type lesions (50%±75%) (Bachelez et al, 1995; Curco et al,
Manuscript received December 13, 2000; revised May 13, 2001;
accepted for publication May 23, 2001.
Reprint requests to: Professor M. Beylot-Barry, Equipe Histologie et
Pathologie MoleÂculaire, E.A. 2406, Case 8, Bat 3B, UniversiteÂ Victor
Segalen Bordeaux 2, 33076 Bordeaux Cedex, France. Email: marie.beylot-
barry@histo.u-bordeaux2.fr
Abbreviations: CR, complete remission; DGGE, denaturing gradient gel
electrophoresis; MF, mycosis fungoides; PBL, peripheral blood lympho-
cytes; PR, partial remission; SS, SeÂzary syndrome.
0022-202X/01/$15.00 ´ Copyright # 2001 by The Society for Investigative Dermatology, Inc.
920
1997; Muche et al, 1997; Delfau-Larue et al, 1998a). Moreover, the
absence of a detectable cutaneous T cell clone is associated with a
higher rate of complete remission (CR) (Delfau-Larue et al, 1998a).
The detection of a T cell clone in peripheral blood lymphocytes
(PBL) identical to the cutaneous clone has suggested that MF, even
in the early stages, may be a systemic disease originating in the skin
(Bakels et al, 1992; Muche et al, 1997; Delfau-Larue et al, 2000).
The prognostic meaning of a circulating T cell clone has not been
investigated in the above series of MF/SS. As in MF, a cutaneous T
cell clone has been detected in 79%±100% of nonepidermotropic
pleomorphic CD30± CTCL (Theodorou et al, 1995; Muche et al,
1997) but no correlation with stage or prognosis has been drawn
owing to the recent provisional individualization of such diseases
(Willemze et al, 1997).
The purpose of our study was to determine the frequency of T
cell monoclonality, as determined by PCR in skin and PBL, in a
cohort of CD30± CTCL, according to clinical stage and
clinicopathologic group. The results were studied by comparison
with the outcome of the patients to determine whether the initial
PCR detection of T cell clone in skin, PBL, or both is associated
with a poorer prognosis as an independent factor and may therefore
be relevant for therapeutic strategies.
MATERIALS AND METHODS
Patient selection and staging system Patients with primary CTCL
referred to the two dermatologic departments (Haut-LeÂveÃque and Saint
AndreÂ Hospital) of the University Hospital of Bordeaux were
prospectively included in this study between 1994 and March 2000.
Inclusion criteria consisted of (i) a PCR study on a cutaneous biopsy
representative for the diagnosis of CTCL and performed before any
systemic therapy and (ii) a simultaneous PCR study in the skin and
blood.
The patients were included with informed consent according to the
French Bioethical law as skin and blood analyses were routinely
performed at initial diagnosis. No additional biologic sample was taken
for the purpose of the study. Moreover, the design of the study was
approved by the Clinical Research Delegation of our University Hospital
in January 1994.
The diagnosis of CTCL was made according to the EORTC
classi®cation for primary cutaneous lymphoma (Willemze et al, 1997).
Thus, the cases were separated into MF, SS, and CD30± pleomorphic
CTCL, with either large and medium-sized or small and medium-sized
cells, whereas CD30+ large CTCL (more than 75% of the tumoral cells
expressing the CD30 antigen) were excluded from the study as they are
a distinct clinicopathologic entity.
The initial clinical stage of the patients with MF/SS was determined
using the TNM classi®cation adapted for MF (Bunn and Lamberg,
1979). All the nonepidermotropic CTCL included in our study were
primary CTCL, de®ned by the absence of extracutaneous disease at the
time of diagnosis and within the ®rst 6 mo after diagnosis (Willemze
et al, 1997). They were classi®ed as either localized cutaneous disease
(solitary or several lesions clustered at the same skin site) or diffuse
cutaneous disease.
TCR-g gene rearrangement analysis TCR-g gene rearrangement
was studied by using a GC-clamp multiplex PCR denaturing gradient
gel electrophoresis (DGGE) as previously described (Theodorou et al,
1995). This procedure was originally demonstrated to amplify all possible
TCR-g gene rearrangements, as the primers are consensus and speci®c
for each Vg or Jg segment family (Theodorou et al, 1995). Using
different T cell lines or tumor monoclonal DNA, we also checked by
monoplex PCR followed by sequencing analysis that each Vg or Jg
consensus primer allowed us to amplify a de®ned monoclonal allele. The
value of this procedure has also been demonstrated for the diagnosis of
patients with epidermotropic T cell lymphoma (Theodorou et al, 1995;
Delfau-Larue et al, 1998a, b, 2000). In our hands, the sensitivity
threshold for the detection of a dominant T cell clonal rearrangement
ranged from 2.5% to 5% of clonal cells diluted into polyclonal cells
depending on the rearranged allele. The sensitivity was checked
throughout the study by including in each assay a dilution of DNA
extracted from Jurkat cell line (kindly provided by P. Cornillet, Reims,
France). PCR study was performed on DNA extracted from the frozen
half of cutaneous biopsies processed for histopathologic examination and
on mononuclear blood cells puri®ed by density gradient centrifugation.
Cutaneous biopsies were taken as the most in®ltrated lesion in each
patient and the presence of an epidermotropic CTCL in®ltrate was
checked on frozen sections before DNA extraction. Samples were
interpreted either as polyclonal (presence of a smear) or as monoclonal
(presence of one to four dominant or discrete bands depending on the
formation of homoduplicities or heteroduplicities) (Theodorou et al,
1995). When a T cell clone was detected in the cutaneous specimen, it
was considered as the reference clone for comparison with the T cell
clone possibly detected in PBL. Indeed, the use of GC-clamp primers
and DGGE in our PCR assay resulted in a genetic imprint speci®c for
the TCR-g allele that was useful for comparison of both the size and
sequence of PCR products (Theodorou et al, 1995). This allowed us to
classify the cases in three main groups: group 1, polyclonal pro®le in the
skin whatever the pro®le in blood; group 2, T cell clone in skin without
an identical clone in PBL (where PCR detected either a polyclonal
pro®le or a different T cell clone); group 3, identical T cell clone in skin
and PBL according to DGGE analysis.
Statistical analyses The prognostic value of clonality was assessed
using survival analysis methods. The entry date of our study sample was
the histologic diagnosis of MF. Patients were followed up every 6 mo.
They were considered lost to follow-up if their last follow-up occurred
more than 6 mo before September 2000. Disease progression was
evaluated retrospectively by the two physicians who have followed all
patients. The interval to disease progression was calculated from the
entry date to the date of diagnosis of ``events'' [absence of response to
treatment, progression of cutaneous lesions, or occurrence of
extracutaneous involvement (both leading to change in the stage of the
disease)] or to the date of death. Patients with complete or partial
remission (CR/PR) until last clinical follow-up were right-censored.
The study focused on the frequency and the prognostic value of initial T
cell clone PCR detection and did not consider the different treatments
received by the patients. Indeed, treatments were administered according
to the initial clinical stage and could not therefore be evaluated as an
independent variable as no therapeutic trial was conducted prospectively.
The multivariate analysis of clonality effect was therefore adjusted on
age, gender, and clinical stage. When clinical events other than death
occurred between two visits, the observations were interval-censored.
Therefore, univariate and multivariate analyses were performed using a
proportional hazards model with a penalized likelihood approach (Joly
et al, 1998), and comparison with a right-censored approach using SAS
software, version 6.12 (Allison, 1995), showed no signi®cant difference
between these two approaches. The proportional hazards assumption was
graphically checked by examining hazard functions.
RESULTS
Overall, 85 patients (60 men and 25 women) were included. The
average age was 59 y (18±92 y). According to the clinicopathologic
diagnosis based on EORTC classi®cation (Willemze and Meijer,
2000), the patients were classi®ed as 67 MF including eight
transformed MF, seven SS, and 11 CD30± pleomorphic CTCL
(either small/medium-sized or medium/large-sized cells: n = 8 and
n = 3, respectively). The TNM classi®cation (Bunn and Lamberg,
1979) allowed us to classify the 67 patients with MF as 18 stage Ia,
25 stage Ib, four stage IIa, eight stage IIb, six stage IIIa, three stage
IIIb, two stage IVa, one stage IVb. The seven SS were classi®ed as
six stage IVa and one stage IIIb. Stages Ia±IIa were considered as
early stages and stages IIb±IVb (including SS) as advanced stages.
The 11 CD30± nonepidermotropic CTCL were classi®ed as
localized (n = 5) and diffuse (n = 6) skin disease.
T cell clone PCR detection frequency according to clinico-
pathologic group and initial stage of disease According to
the clinicopathologic group, cutaneous T cell monoclonality
frequency varied as follows: 69% for MF (46 of 67), 100% for SS
(seven of seven), and 55% for CD30± CTCL (six of 11).
Mycosis fungoides and SeÂzary syndrome (Fig 1) Regardless of the
initial stage of the disease, 72% (53 out of 74) of the patients with
MF/SS had a cutaneous T cell clone and 54% (40 of 74) had a
blood T cell clone. The T cell clone PCR detection frequency
varied according to the clinical stage, from the early stages (Ia±IIa:
57% in the skin and 42% in PBL) to the advanced stages (IIb±IV SS:
96% in the skin and 74% in PBL). When detected, the T cell clone
in PBL was signi®cantly more frequently identical to the cutaneous
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reference clone in advanced than in early stages (17 of 20 vs 7 of 20,
p = 0.001). Then, 15% of early MF had an identical clone in skin
and PBL versus 63% for advanced MF.
According to the clonality results (Table I), the patients were
classi®ed as: group 1, 42% of early stages, 4% of advanced stages;
group 2, 43% of early stages, 33% of advanced stages; group 3, 15%
of early stages, 63% of advanced stages.
Statistical analysis demonstrated that clinical stage (early/
advanced stages) and clonality were highly associated (Pearson
c2 = 21.7, p < 10±4).
CD30±Nonepidermotropic CTCL Whatever the stage, 55% (six of
11) of patients showed T cell monoclonality in skin and 36% (four
of 11) in PBL. The clonality results seemed to vary between
patients with localized or diffuse cutaneous disease as, respectively,
none out of ®ve and three out of six had an identical T cell clone in
skin and blood. Moreover, four of the ®ve cases with localized
cutaneous disease had a polyclonal pro®le in the skin. Then, ®ve
cases were in group 1 (four localized and one diffuse cutaneous
disease), three in group 2 (one localized and two diffuse cutaneous
disease), and three in group 3 (all had diffuse cutaneous disease).
Lastly, the results of clonality were not found to be associated with
the histologic subtype (three cases with pleomorphic medium/
large-sized cells: two in group 1 and one in group 3).
Outcome according to the PCR results The median follow-
up time in the study was 32 mo (ranging from 5 to 77 mo) and was
comparable between the different clinical stages (Table II). Death
occurred in 10 patients including seven MF, two SS, and
one CD30± CTCL, and as it was a rare event, survival was not a
good criterion to evaluate the prognostic value of PCR detection
in CTCL. Therefore, the prognostic evaluation was performed as
described above: CR/PR as opposed to absence of response to
treatment or progression. Stable disease (absence of response to
treatment) was retained as an ``event'', grouped with
``progression''. Indeed, all the patients at early stages with a stable
disease (n = 4) ®nally progressed or died after 8±25 mo, whereas
those at late stages with a stable disease progressed (n = 6) or did
not respond to treatment (n = 4). By de®nition, the patients
included did not receive systemic treatment before the PCR study.
Treatments were administered according to clinical stage and
were relatively homogeneous within each stage group for most of
the patients, but no prospective therapeutic trial was simultaneously
performed. At early stages (Ia±IIa), most of the patients were treated
by topical therapies (corticosteroids, topical nitrogen mustard,
carmustine, psoralen with ultraviolet A). At advanced stages,
radiotherapy was performed on tumors (IIb, T3), interferon,
chlorambucil, methotrexate, or polychemotherapy were used for
stages IIIa±IVb, and extracorporeal photopheresis or chemotherapy
for SS.
The group of MF/SS included 74 assessable patients. Two MF
Ib, group 1 were lost to follow-up.
First, we compared the status of the patients at the end of the
study. Among the 19 patients in group 1, 17 (89%) achieved CR/
PR. In the 29 patients in group 2, 19 (65%) experienced CR/PR.
In the 24 patients in group 3, CR/PR was obtained in only six
(25%).
Factors associated with disease progression were studied with
special emphasis on clonality results (Table III, Fig 2). Neither age
nor sex was associated with disease progression. Conversely, clinical
stage (early versus advanced) was an important prognostic factor, as
the risk of disease progression was higher in advanced compared to
early stages in univariate [hazard ratio (HR) 6.7, p < 10±4] and
multivariate (HR = 5, p = 8 3 10±4) analyses. The clonality results
were also found to be a signi®cant variable for the risk of
progression in univariate (p < 10±4) as in multivariate (p = 0.02)
Table I. PCR study in MF/SS according to initial clinical stage (N = 74)
Group 1
No T cell
clone in skin
n (%)
Group 2
T cell clone
in skin only
n (%)
Group 3
Identical T cell clone
in skin and blood
n (%)
Total
n (%)
Ia
Ib
IIa
Early stages
81
115
1
206 (42)
73
103
31
207 (43)
3
4
0
7 (15)
18
25
4
47 (100)
IIb
IIIa
IIIb
IVa
IVb
SS
Advanced stages
0
0
1
0
0
0
1 (4)
42
2
1
1
11
0
93 (33)
4
4
1
1
0
7
17 (63)
8
6
3
2
1
7
27 (100)
aNumbers in exponent: number of cases with clonal but not identical rearrangement in PBL
Figure 1. Ampli®cation of the TCR-g gene rearrangement. PCR
products were run on a DGGE polyacrylamide gel and were ethidium
bromide stained. S, skin; B, blood; T, positive control (Jurkat cell line).
Group 1 (cases 1 and 2): A polyclonal pro®le was observed in skin with
either a polyclonal pro®le (case 1) or a T cell clone (case 2) in blood.
Group 2 (cases 3 and 4): A monoclonal rearrangement of the TCR-g
gene in skin with either a polyclonal pro®le (case 3) or a different T cell
clone (case 4) in blood. Group 3 (case 5): An identical T cell clone was
observed in skin and blood.
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analysis. On comparison of groups 2 and 3 (clonality in skin
whatever the results in PBL) with group 1 (cutaneous polyclonality)
we observed a signi®cantly higher risk of progression in univariate
analysis (HR = 3.6, p = 0.02) but not in multivariate analysis.
When a T cell clone was detected only in the skin, it was not
statistically associated with disease progression. On the other hand,
when the cutaneous clone was associated with an identical T cell
clone in blood (group 3), it was associated with a poorer prognosis,
compared with an isolated cutaneous T cell clone (group 2)
(HR = 3.5, 95% con®dence interval 1.5±8.2). Thus, multivariate
analysis demonstrated that an identical T cell clone in PBL and skin
consisted in an independent risk factor for disease progression in
MF/SS.
Nonepidermotropic CD30± CTCL were analyzed separately as
their clinical behavior and prognosis are different from MF/SS.
Moreover, the size of this group did not allow adequate statistical
analysis.
Among the ®ve patients in group 1 (polyclonal cutaneous
pro®le), the four patients with localized cutaneous disease were in
CR/PR whereas the patient with diffuse cutaneous disease
progressed. All the patients in group 2 (isolated cutaneous T cell
clone), including one localized and two diffuse cutaneous disease,
were in CR/PR. Lastly, only one of the three patients (diffuse
cutaneous disease) in group 3 (identical clone in skin and blood)
was in CR whereas the other two had progressed (n = 1) or were
deceased (n = 1).
DISCUSSION
In this series, patients with MF/SS and CD30± nonepidermotropic
CTCL referred to our departments were evaluated with no bias of
Table III. Prognostic factors of disease progression in MF/SS (N = 74)a
Description Univariate analysisb Multivariate analysisb
Variable N No. of events (%) HR p HR 95% CI p
Sex:
Female
Male
23
51
10 (43)
22 (43)
1.0
1.1 0.74
1.0
0.96 0.44±2.1
0.92
Age:
< 60 y
> 60 y
37
37
12 (32)
20 (54)
1.0
1.9 0.08
1.0
1.1 0.51±2.4
0.78
Clinical stage:
Early
Advanced
47
27
10 (21)
22 (81)
1.0
6.7
< 10±4
< 10±4
1.0
5.0
2.0±12.7 8.10±4
0.02
Clonality:
No T cell clone in skin
T cell clone in skin only
Identical T cell clone
21
29
24
4 (19)
10 (34)
18 (75)
0.52
1.0c
3.9
1.02
1.0c
3.4
0.28±3.64
1.4±9.9
in skin and blood
aHR, hazard ratio; CI, con®dence interval.
bProportional hazards model.
cReference.
Table II. Median follow-up according to the clinical stage
in MF/SS (N = 74)
Stage Number of cases Median follow-up (range)
Ia 18 47.5 (29±77 mo)
Ib 25 29 (5±60 mo)
IIa 4 27.5 (24±40 mo)
IIb 8 15.5 (6±61 mo)
IIIa 6 24 (11±37 mo)
IIIb 3 45 (24±57 mo)
IV 3 54 (6±67 mo)
SS 7 30 (6±65 mo)
Total 74 32 (5±77 mo)
Figure 2. Statistical analysis. (A) Probability of progression of the
patients with MF/SS according to the initial clinical stage (early stage
versus late stage). (B) Probability of progression of the patients with MF/
SS according to the clonality results in skin and blood (no T cell clone
in skin, T cell clone in skin only, identical T cell clone in skin and
blood).
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inclusion depending on the clinical presentation or histologic
subtype. The frequency of T cell monoclonality in skin and blood
specimens was determined at initial diagnosis time and its
prognostic value was retrospectively analyzed according to fol-
low-up every 6 mo of each patient by the two physicians who
followed all patients. Skin or blood T cell monoclonality was found
to parallel the initial stage of the disease prior to therapy. The
presence of an identical T cell clone in skin and blood was
demonstrated by multivariate analysis as an independent factor for
disease progression.
Frequency of T cell clone according to stage and
clinicopathologic group Molecular genetic techniques have
demonstrated the clonal nature of cutaneous lymphomatous cells in
CTCL. This was ®rst revealed in the tumoral stage of MF and in SS
by southern blot analysis of TCR-b gene rearrangement (Weiss
et al, 1985; Ralfkiaer et al, 1987). This technique allowed the
detection of T cell monoclonality in most (> 90%) advanced stages
(erythroderma, tumoral lesions) but infrequently at early stages with
nonin®ltrated patch lesions (Weiss et al, 1989; Whittaker et al,
1991; Zelickson et al, 1991; Therune et al, 1993). Using PCR, a
monoclonal TCR-g gene rearrangement was detected in most
cutaneous specimens of MF/SS (50%±100% according to the stage)
(Wood et al, 1994; Theodorou et al, 1995; Muche et al, 1997;
Delfau-Larue et al, 1998a, 2000). The overall 69% T cell
monoclonality in our MF/SS cases is an intermediate value
between the frequency of 53% reported by Theodorou et al
(1995), who studied mostly patients with patches and plaques, and
that of 90% reported by Wood et al (1994), who studied patients at
advanced stages. Delfau-Larue et al (1998a), who detected a
cutaneous T cell clone in 62% of patients with MF in variable
stages (mostly early stages), suggested that T cell monoclonality may
be directly related to the density of lymphomatous cells in the skin
in®ltrate but did not ®nd a correlation with cutaneous or
extracutaneous extension. Muche et al (1997) found a cutaneous
T cell monoclonality in 70%±75% of MF/SS whatever the stage.
Our series of a representative sample of MF/SS patients with an
average age of 58 y is therefore the ®rst that statistically
demonstrates a signi®cant relationship between clonality and
clinical stage.
Using PCR, several groups have shown the presence of
monoclonal circulating T cells in SS and at advanced stages of
MF, although less frequently at the early stages such as MF Ia
(Wood et al, 1994; Theodorou et al, 1995; Veelken et al, 1995;
Curco et al, 1997; Muche et al, 1997; Delfau-Larue et al, 2000;
Fraser-Andrews et al, 2000). Our study also showed that blood T
cell monoclonality was correlated with initial clinical stage prior to
therapy in unselected patients with CTCL (54% of all cases: 42% in
early stages and 74% in advanced stages). The PCR-DGGE
technique allowed us to compare the electrophoretic pro®le of
blood T cell clonal rearrangement with the cutaneous one. This
revealed that identical monoclonal T cells are detectable before
therapy both in skin and blood more frequently at advanced stages
(63%) than in patients at early stages (15%) of MF/SS. Our data are
in accordance with the rates of blood T cell monoclonality (45%)
reported by Fraser-Andrews et al (2000) in MF/SS, but their blood
specimens were not studied in comparison with cutaneous ones,
except for one case studied with comparative sequence analysis,
which is a laborious procedure for routine analysis. Similar to our
PCR-DGGE, Muche et al (1997) used heteroduplex-loaded tem-
perature gradient gel electrophoresis without systematic sequencing
and obtained a rate of detection of blood T cell clonality ranging
from 46% in early stages (MF Ia) to 100% in advanced stages (MF
II±IV). Recently, Delfau-Larue et al (2000), also using the same
multiplex PCR-DGGE technique, reported that rates of blood
clonality were variable according to the clinical stage (4%±68%
according to the stage).
Moreover, we detected monoclonal blood T cells different to the
cutaneous clone, especially at early MF stages (28% vs 11% in late
stages). Muche et al (1997) have previously reported such unrelated
PBL T cell clones in two of 58 specimens in a parallel PCR study of
skin and blood. Delfau-Larue et al (2000) have recently shown that
unrelated PBL T cell clones may indeed be detected in up to 33%
of patients with MF or with benign cutaneous in®ltrates.
Moreover, these unrelated PBL T cell clones were more frequently
observed in patients over 60 y of age, in accordance with the
detection of monoclonal T cells in PBL of normal elderly donors
over 65 y of age (Posnett et al, 1994). In our study, the mean age of
the 34 patients without a blood T cell clone (53.5 y) did not
signi®cantly (p = 0.15) differ from that of the 16 patients with an
unrelated blood T cell clone (68.5 y). An unrelated PBL T cell
clone appeared more frequently in patients with early stage MF
(28%) than in those with advanced disease (11%), suggesting that it
may correspond to an activated CD8+ clonal population as a host
immune response to the tumoral clone (Asadullah et al, 1997;
Muche et al, 1999). Immunophenotyping of blood cells, especially
at early stages of MF, might be useful to determine whether clonal
T cells belong to CD4+ or CD8+ lymphocytes and to analyze
their T cell receptor repertoire.
Interestingly, all cases of SS had an identical T cell clone in skin
and blood whereas the number of circulating SeÂzary cells was
below 10% in three out of seven patients (our personal results).
Blood clonality has been proposed as a major diagnostic criterion in
SS (Willemze et al, 1997; Fraser-Andrews et al, 1998) rather than
the subjective morphologic identi®cation of SeÂzary cells (Weinberg
et al, 1995). Moreover, monoclonal T cells may be detectable in
blood but not in skin specimens of patients with SS (Muche et al,
1997; Willemze et al, 1997). Such a situation was not observed in
our series.
Very few data are available for nonepidermotropic CTCL, with a
detection frequency of TCR-g rearrangement that varies from 50%
to 100% in the skin (Theodorou et al, 1995; Dommann et al, 1996;
Muche et al, 1997) and from 50% to 75% in PBL (Theodorou et al,
1995; Muche et al, 1997). These studies lacked information about
histologic subtype, however, including CD30 phenotype and stage
of lymphoma. The 55% rate of cutaneous T cell monoclonality in
nonepidermotropic CD30± CTCL is in accordance with the above
data. The presence of an identical blood T cell clone in three out of
11 patients without extracutaneous disease suggests an early blood
circulation of tumoral cells, as in MF. The frequency of T cell clone
in skin and blood also appeared to be related to the extent of the
disease (localized versus diffuse cutaneous disease). Such results
underline the similarities between MF and nonepidermotropic
CD30± CTCL, especially for the pleomorphic small/medium-sized
subtype (eight out of 11 patients), which is a provisional entity in
the EORTC classi®cation (Willemze et al, 1997).
An identical cutaneous and blood T cell clone is an
independent prognostic factor in MF/SS Whereas several
groups have shown T cell monoclonality of cutaneous or blood
specimens in MF/SS, only two groups have recently demonstrated
its signi®cant prognostic value (Delfau-Larue et al, 1998a; Fraser-
Andrews et al, 2000). The ®rst study showed that the detection of
T cell monoclonality in cutaneous lesions of early MF is predictive
of the achievement of CR (Delfau-Larue et al, 1998a). CR is a
highly variable notion according to time-point follow-up and
de®nition of CR duration, however. Moreover, CR was not found
to be correlated with a better survival in MF (Kaye et al, 1989; Kim
et al, 1999). Therefore, CR may not necessarily be the major
therapeutic goal, which is rather to improve either survival or the
quality of life by obtaining a regression of cutaneous lesions. The
second study showed that the presence of a blood T cell clone was
an independent prognostic marker in MF according to the 10 y
survival (50% in patients without a detectable blood clone versus
30% in those with a PBL clone), whereas the 5 y survival was not
statistically different, as in our study (Fraser-Andrews et al, 2000).
For the above reasons, we found it more reliable to assess the
prognostic value of the PCR study in terms of disease progression
rather than CR or survival. By studying T cell clonality both in skin
and blood specimens at the time of diagnosis, we found two main
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prognostic factors for MF/SS: (i) the initial stage of the disease was
con®rmed as an independent prognostic factor (Diamandidou et al,
1999; Zackheim et al, 1999); (ii) the presence of an identical clone
in skin and blood. First, we showed that the presence of a
cutaneous T cell clone whatever the results in PBL had a signi®cant
unfavorable value only by univariate analysis. When the prognostic
value of an isolated cutaneous T cell and an identical T clone in
skin and blood was successively analyzed, we demonstrated by
multivariate analysis that only the presence of an identical T cell
clone in skin and blood is an independent prognostic factor. The
cytologic detection of peripheral blood abnormal T cells is a marker
of poor prognosis in MF/SS but such detection is not a
reproducible or sensitive assay (Schechter et al, 1987; Kim et al,
1995). In our study, the detection of a blood T cell clone had a
prognostic value even for early MF stages and in the absence of
cytologically detectable abnormal peripheral blood cells. As only
identical blood and skin T cell monoclonality had a prognostic
value, our study points to the need for using PCR analysis such as
DGGE allowing a direct comparison of the TCR-g rearranged
allele in routine analysis (Theodorou et al, 1995). The sensitivity
threshold of around 5% for our technique allowed prognostic study
although the prognostic signi®cance of a lower threshold
(sensitivity of 0.1%), such as in the study of Muche et al (1997),
remains to be evaluated. The emergence of real-time quantitative
PCR will also allow standardized clonality analyses to be obtained,
which should be useful for prognostic studies (Verhagen et al,
2000).
In the absence of identi®ed recurrent molecular abnormality in
MF/SS, TCR-g gene rearrangement analysis is so far the unique
molecular analytical technique for managing these lymphomas, as a
parallel PCR study of skin and blood specimens appears in our
study of clinical interest at diagnosis for evaluating the risk of
progression. The subdivision of patients according to initial
molecular staging would help to evaluate therapeutic strategies.
Therefore, the detection of circulating tumoral lymphocytes in
early stages of MF would allow evaluation of the interest of
systemic immunologic rather than local therapies before the disease
is clinically widespread. A fully prospective study, with simultan-
eous therapeutic trials, needs to be done to con®rm our ®ndings
and to include treatment variables in the statistical analysis.
Moreover, longitudinal studies would determine whether a mol-
ecular follow-up will de®ne patients with a higher risk of
progression as the clonal TCR gene rearrangement usually remains
unchanged over time (Bottaro et al, 1994; Theodorou et al, 1995;
Delfau-Larue et al, 1998b).
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